Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial
LAMB with or without subsequent azole prophylaxis could be an alternative option for fungal prophylaxis for patients with AML in whom azoles are contraindicated or not tolerated. Sorafenib does not appear to be associated with an increased risk of IFD.
Authors
- Andrew H. Wei (ORCID: https://orcid.org/0000-0002-7514-3298)
- Ian Bilmon (ORCID: https://orcid.org/0000-0002-6375-0138)
- Monica A. Slavin (ORCID: https://orcid.org/0000-0002-8443-314X)
- Andrew W. Roberts (ORCID: https://orcid.org/0000-0002-7341-5720)
- Chin Fen Neoh (ORCID: https://orcid.org/0000-0003-2462-2958)
- Glen Kennedy (ORCID: https://orcid.org/0000-0002-7171-0435)
- Michelle K. Yong (ORCID: https://orcid.org/0000-0002-8692-4145)
- Anthony P. Schwarer
- Simon He
- Leesa Rowley
Institutions
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- Royal Brisbane and Women's Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- Westmead Hospital (AU)
- Eastern Health (AU)
- Australasian Leukaemia and Lymphoma Group (AU)
- Austin Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/jac/dkaf385
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00